Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.71 |
| ▸ | HTT | P42858 | 1/20 | 0.71 |
| ▸ | PLK1 | P53350 | 1/20 | 0.58 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.56 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 5/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2671850 | 0.88 | NPC1 (0.55) | ALOX15HTTALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL29878621 | 0.88 | NPC1 (0.55) | ALOX15HTTALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL20127263 | 0.88 | ALOX15 (0.70) | ALOX15HTTPLK1TAS1R3TAS1R1 | |
| SCHEMBL14046318 | 0.86 | ALOX15 (0.64) | ALOX15HTTPLK1TAS1R3TAS1R1 | |
| SCHEMBL1696434 | 0.86 | ALOX15 (0.59) | ALOX15HTTPLK1TAS1R3TAS1R1 | |
| SCHEMBL28830798 | 0.84 | MAPT (0.67) | ALOX15HTTLMNASMN1; SMN2NPC1 | |
| SCHEMBL12600101 | 0.83 | ALOX15 (0.60) | ALOX15HTTPLK1TAS1R3TAS1R1 | |
| SCHEMBL265015 | 0.83 | ALOX15 (1.00) | ALOX15HTTPLK1TAS1R3TAS1R1 | |
| SCHEMBL30718649 | 0.83 | ALOX15 (1.00) | ALOX15HTTPLK1TAS1R3TAS1R1 | |
| SCHEMBL21816443 | 0.83 | ALOX15 (0.63) | ALOX15HTTPLK1TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10224485-B2 | Process for preparing a crystalline organic semiconductor material | BASF SE (DE) | 2019-03-05 | — | — | US | claimed |
| US-20170012208-A1 | ORGANIC SEMICONDUCTOR FORMULATIONS | USINVEST LLC | 2017-01-12 | — | — | US | claimed |
| WO-2004072046-A2 | QUINOLINE DERIVATIVES AND THEIR USE FOR MODULATION OF LXR ACTIVITY | CAREX S.A. (FR) | 2004-08-26 | — | — | WO | claimed |
| CN-120118096-A | Synthesis and purification method of levofloxacin hydrochloride | 江西大地制药有限责任公司 | 2025-06-10 | — | — | CN | disclosed |
| US-20240254110-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | CANCER RESEARCH TECH LTD (GB) | 2024-08-01 | — | — | US | disclosed |
| CN-112920183-B | Compounds as KRAS-G12C inhibitors and uses thereof | 南京圣和药业股份有限公司 | 2024-07-19 | — | — | CN | disclosed |
| CN-117820226-A | Compounds for the treatment of kinase dependent disorders | 埃克塞里艾克西斯公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-117624045-A | Compounds for the treatment of kinase dependent disorders | 埃克塞里艾克西斯公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-117603138-A | Compounds for the treatment of kinase dependent disorders | 埃克塞里艾克西斯公司 | 2024-02-27 | — | — | CN | disclosed |
| CN-117402114-A | Compounds for the treatment of kinase dependent disorders | 埃克塞里艾克西斯公司 | 2024-01-16 | — | — | CN | disclosed |
| US-11787786-B2 | Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-10-17 | — | — | US | disclosed |
| US-5236919-A | Inhibitorsof enzyme 5-lipoxygenase | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-08-17 | — | — | US | disclosed |
| US-5134148-A | Heterocycles for use as inhibitors of leukotrienes | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-07-28 | — | — | US | disclosed |
| US-5089495-A | Lipoxygenase inhibitors | IMPERIAL CHEMICAL INDUSTRIES PLC (FR) | 1992-02-18 | — | — | US | disclosed |
| US-4968803-A | FLUORINE AS OXIDANT | ALLIED-SIGNAL INC. (US) | 1990-11-06 | — | — | US | disclosed |
| EP-0385662-A2 | Heterocycles with inhibitory activity of 5-lipoxygenase | ZENECA LIMITED (GB) | 1990-09-05 | — | — | EP | disclosed |
| EP-0381375-A1 | Heterocyclic derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-08-08 | — | — | EP | disclosed |
| US-4734407-A | ANIMAL GROWTH REGULATORS | BAYER AKTIENGESELLSCHAFT (DE) | 1988-03-29 | — | — | US | disclosed |
| US-4299894-A | Electrically photosensitive materials and elements for photoelectrophoretic imaging processes | EASTMAN KODAK COMPANY (US) | 1981-11-10 | — | — | US | disclosed |
| US-3959473-A | DIURETIC | U.S. PHILIPS CORPORATION (US) | 1976-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240254110-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | HSF1, HSP90AB1, HSPB1 | ALOX15 1576/4885HTT 528/4885PLK1 608/4885 |
| US-11787786-B2 | Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1 | HSF1, HSP90AB1, HSPB1 | ALOX15 1576/4885HTT 528/4885PLK1 608/4885 |
| US-10224485-B2 | Process for preparing a crystalline organic semiconductor material | STOM, SPOP, TTR | ALOX15 4022/4885HTT 2419/4885PLK1 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.